ALBRIOZA Commercial Launch

photo in memory of Mick, a husband and father, who was a gifted tattoo artist and musician PHOENIX Phase 3 Trial Designed to provide additional safety and efficacy data on RELYVRIO for the treatment of ALS to further support our global regulatory efforts Nov 2021 First participants dosed Feb 2023 Mid- 2024 Trial completed enrollment with 664 participants Topline data anticipated AMYLYX 19

View entire presentation